MetaCap

Faeth Therapeutics (FTH) vs Vanda Pharmaceuticals (VNDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Faeth Therapeutics (FTH) has outperformed Vanda Pharmaceuticals (VNDA) over the past year, losing 9.6% versus a loss of 28.2%. Over five years, VNDA leads with a -79.2% price change compared with -95.0% for FTH. Vanda Pharmaceuticals is the larger company by market cap ($208.3 million vs $203.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FTH-9.64%VNDA-28.23%
+379%+166%-48%
Nov 21, 20251 yearNov 20, 2026
FTH-95.34%VNDA-79.69%
+11%-45%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FTH versus VNDA key metrics
MetricFTHVNDA
Share price$7.88$3.45
Market cap$203.65M$208.32M
1-day change-9.32%-6.13%
YTD return-26.15%-60.94%
1-year return-9.64%-28.23%
5-year return-94.96%-79.18%
Forward P/E—17.22
EPS (TTM)$-22.50$-4.62
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$216.10M
Revenue growth (YoY)—+8.72%
Net income (latest FY)$-21.09M$-220.47M
Gross margin—93.96%
Operating margin—-69.95%
Net margin—-102.02%
52-week high$42.14$9.94
52-week low$7.45$3.42
Distance from 52-week high-81.30%-65.34%
Analyst consensusstrong_buynone
Avg. price target upside+612.56%+233.82%
Average volume500.25K1.06M
Shares outstanding25.84M60.47M
Employees29533
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FTH has outperformed VNDA by 18.6 percentage points over the past year.

About Faeth Therapeutics

FTH stock →

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About Vanda Pharmaceuticals

VNDA stock →

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.

Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees

FTH vs VNDA FAQ

Which is bigger, Faeth Therapeutics or Vanda Pharmaceuticals?

Vanda Pharmaceuticals (VNDA) is larger, with a market capitalization of $208.32M compared with $203.65M for Faeth Therapeutics (FTH).

Which stock has performed better over the past year, FTH or VNDA?

FTH returned -9.64% over the past 12 months, compared with -28.23% for VNDA (price return, excluding dividends). Past performance does not predict future results.

Are Faeth Therapeutics and Vanda Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons